Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders

American Journal of Nephrology

Volumn 22, Issue 5-6, 2002, Pages 429-436

  Opatrný Jr , Karel ^a   Zemanová, Pavlína ^a   Mareš, Jan ^a   Vít, Ladislav ^a   Opatrná, Sylvia ^a   Šefrna, František ^a   Hejda, Václav ^a   Tomšů, Martina ^a   Eiselt, Jaromír ^a   Massry, Shaul G ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Chronic renal failure; Fibrinolysis; Metabolism; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; DESMOPRESSIN; FIBRINOLYTIC AGENT; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; ENZYME ACTIVITY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; HUMAN TISSUE; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANK SUM TEST; REGRESSION ANALYSIS; THROMBOSIS;

AGED; APOLIPOPROTEIN A-I; DEAMINO ARGININE VASOPRESSIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FIBRINOLYSIS; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENAL DIALYSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0036976976     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065270     Document Type: Article

References (54)

1. Davies MJ: The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996;82:1-32.
2. Fujii S: PAI-1 in thrombosis and arteriosclerosis. Fibrinolysis Proteolysis 1997;11(suppl 2):137-140.
3. Kohler HP, Grant PJ: Plasminogen-activator inhibitor type I and coronary artery disease. N Engl J Med 2000;342:1792-1801.
4. Hamsten A, Wiman B, Faire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
5. Nguyen G, Horellou MH, Kruithof EK, Conard J, Samama MM: Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis, a study in 83 patients with confirmed deep venous vein thrombosis. Blood 1988;72:601-605.
6. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCV: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
7. Hoffmeister HM, Jur M, Ruf-Lehmann M, Helber U, Heller W, Seipel L: Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 1998;31:547-551.
8. Raine AEG, Margreiter R, Brunner FP, Ehrich JHH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderrabano F: Report on Management of Renal Failure in Europe, XXII. Nephrol Dial Transplant 1991;7(suppl 2):7-32.
9. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1991;32(suppl 3):112-119.
10. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Vascular Access. Update 2000. Am J Kidney Dis 2001;37(suppl 1):137-180.
11. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risk in chronic hemodialysis patients. Kidney Int 2000;58:353-362.
12. Winter M, Needham J, Mackie I, Cameron JS: Impaired vessel wall response to venous occlusion in patients with chronic renal failure on maintenance hemodialysis. Clin Nephrol 1984;22:307-313.
13. Brommer EJP, Schicht I, Wijnagaards G, Verheijen JH, Rijken DC: Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemost 1984;52:311-314.
14. Opatrný K Jr, Vít L, Opatrný K, Šefrna F, Válek A: Fibrinolysis in patients with chronic renal failure after 1-deamino-8-D-arginine vasopressin. J Nephrol 1991;4:233-238.
15. Opatrný K Jr, Vít L, Opatrná S, Bodláková B, Sulková S, Opatrný K: Hypofibrinolysis after stimulation by venous occlusion in hemodialysis patients and the effect of erythropoietin. Nieren- Hochdruckkrh 1995;24:324-328.
16. Irish AB: Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997;46:36-40.
17. Tomura S, Nakamura Y, Mayumi D, Ando R, Ida T, Chida Y, Ootsuka S, Shinoda T, Yanagi H, Tsuchia S, Marumo F: Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996;27:848-854.
18. Opatrný K Jr, Mareš J, Vít L, Šefrna F, Eiselt J, Opatrná S, Racek J, Hejda V, Tomšů M: Fibrinolysis and metabolic disturbances in hemodialysis patients. Nieren- Hochdruckkrh 2001;30:505-515.
19. Eliasson M, Asplund K, Evrin PE, Lindahl B, Lundblad D: Hyperinsulinemia predicts low tissue plasminogen activator activity in healthy population: The Northern Sweden MONICA Study. Metabolism 1994;43:1579-1586.
20. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-2879.
21. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow EF: Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994;14:438-442.
22. Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E: Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. Arterioslcer Thromb 1991;11:629-638.
23. Massry SG: Parathyroid hormone as a uremic toxin; in Massry SG, Glassock RJ (eds): Textbook of Nephrology. Baltimore, Williams & Wilkins, 1995, pp 1270-1303.
24. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979;59:8-13.
25. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
26. Pajunen P, Taskinen MR, Nieminen MS, Syvanne M: Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol 2000;86:1080-1085.
27. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104-109.
28. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence. Circulation 1998;9:2213-2221.
29. Babazono T, Miyamae M, Tomonaga O, Omori Y: Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Adv Perit Dial 1996;12:120-125.
30. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
31. Loskutoff DJ, Mimuro J: Type 1 plasminogen activator inhibitor; in Haber E, Braunwald E (eds): Thrombolysis. New York, Mosby Year Book, 1991, pp 438-442.
32. Juhan-Vague I, Alessi MC, Vague P: Increased plasminogen activator inhibitor 1 levels: A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-462.
33. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK: Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995;91:284-290.
34. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000;89:221-228.
35. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML: Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985;39:1-8.
36. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJ: Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983;309:385-389.
37. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
38. Van Tellingen A, Grooteman MPC, Bartels PCM, Van Limbeek J, Van Guldener C, Ter Wee PM, Nubé MJ: Long-term reduction of plasma homocysteine levels by superflux dialyzers in hemodialysis patients. Kidney Int 2001:59:342-347.
39. Welch GN, Loscalzo J: Mechanism of disease: Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
40. Haraki T, Takegoshi T, Kitoh C, Kajinami K, Wakasugi T, Hirai J, Shimada T, Kawashiri M, Inazu A, Koizumi J, Mabuchi H: Hyperhomo-cysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. Clin Nephrol 2001;56:132-139.
41. Shemin D, Lapane KL, Bausserman EK, Kahn S, Dworkin L, Bostom AG: Plasma total homo-cysteine and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol 1999;10:1095-1099.
42. Oishi K, Nagake Y, Yamasaki H, Fukuda S, Ichikawa H, Ota K, Makino H: The significance of serum homocysteine levels in diabetic patients on hemodialysis. Nephrol Dial Transplant 2000;15:851-855.
43. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000;101:1506-1511.
44. Davi G, Belvédère M, Vigneri S, Catalano I, Gaimmarresi C, Roccaforte S, Consoli A, Mezzeti A: Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996;76:34-37.
45. Stiko-Rahm A, Wiman I, Hamsten A, Nilsson J: Secretion of plasminogen activator I from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;10:1067-1073.
46. Škrha J, Hodinář A, Kvasnička J, Hilgertová J: Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet Med 1996;13:800-805.
47. Zhang J, Ren S, Shen GX: Glycation amplifies lipoprotein (a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis 2000;150:299-308.
48. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997;15:442-447.
49. Matsubara Y, Hayakawa T, Tsuda T, Takeshita E, Watanabe G, Murata M, Watanabe K, Ikeda Y: Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 in healthy Japanese population. Blood Coagul Fibrinolysis 2000;11:115-120.
50. Irish AB, Thompson CH: The effects of gemfibrozil upon the hypercoagulable state in dyslipidemic patients with chronic renal failure. Nephrol Dial Transplant 1996;11:2223-2228.
51. Nordt TK, Schneider DJ, Sobel BE: Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: A potential risk factor for vascular disease. Circulation 1994;89:321-330.
52. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS: Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993;10:27-32.
53. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993;13:1822-1828.
54. Kaysen GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 2001;12:1549-1557.